Exploring the Effects of Opioid-Related Drugs on the Clinical Outcome of Prostate Cancer Patients Via Integrated Bioinformatics Analysis

Molecular Biotechnology, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 20, 2025

Language: Английский

---

The Use of Biologics for Targeting GPCRs in Metastatic Cancers

BioTech, Journal Year: 2025, Volume and Issue: 14(1), P. 7 - 7

Published: Jan. 30, 2025

A comprehensive review of studies describing the role G-protein coupled receptor (GPCR) behaviour contributing to metastasis in cancer, and developments biotherapeutic drugs towards targeting them, provides a valuable resource toward improving our understanding opportunities effectively target this malignant tumour cell adaptation. Focusing on five most common metastatic cancers lung, breast, colorectal, melanoma, prostate we highlight well-studied characterised GPCRs some less studied receptors that are also implicated development cancers. Of approximately 390 relevant therapeutic targeting, as many 125 these have been identified play promoting disease cancer types. GPCR signalling through well-characterised pathways chemokine receptors, emerging data by orphan is integral aspects phenotype. Despite having detailed information their ligands, there only thirteen approved therapeutics specifically for which three small molecules with remainder including synthetic non-synthetic peptides or monoclonal antibodies. This will cover existing potential use antibodies, proteins peptides, nanobodies therapy.

Language: Английский

---

GnRH Peptide Antagonist: Comparative Analysis of Chemistry and Formulation with Implications for Clinical Safety and Efficacy

Pharmaceuticals, Journal Year: 2024, Volume and Issue: 18(1), P. 36 - 36

Published: Dec. 31, 2024

Overexpression of the gonadotropin-releasing hormone receptor (GnRH-R) plays a vital role in advancement reproductive malignancies such as ovarian, endometrial, and prostate cancer. Peptidomimetic GnRH antagonists are substantial therapeutic development, providing fast reversible suppression gonadotropins by directly blocking GnRH-R. Unlike typical agonists, these prevent early hormonal flare, have faster onset action, lower risk cardiovascular problems. These characteristics qualify revolutionary therapy for diseases advanced cancer, endometriosis, uterine fibroids, vitro fertilization procedures. Key peptide authorized regulatory agencies include Cetrorelix, Ganirelix, Abarelix, Degarelix, Teverelix. Assisted technologies (ART) dominated Cetrorelix while Degarelix Abarelix shown significant promise treating Teverelix appears next-generation antagonist with an ideal mix efficacy safety, showing variety hormone-dependent illnesses. This review investigates pharmacological physiology its consequences disease, emphasizing structural advances third- fourth-generation antagonists. All peptide-based were analyzed detail formulation strategy, pharmacokinetics, effectiveness, safety. also emphasizes antagonists’ clinical promise, insights into their evolution possibility future research developing safer, more effective treatments complicated diseases.

Language: Английский

---

A cause-effect relationship between Uterine diseases and Breast cancer: A bidirectional Mendelian randomization study

Heliyon, Journal Year: 2024, Volume and Issue: 10(18), P. e38130 - e38130

Published: Sept. 1, 2024

To explore the cause-effect relationship between uterine diseases (UDs) and breast cancer (BC) underlying mechanism of relationship, enhance understanding association BC UDs.

Language: Английский

---

Case report: A successful live birth after in vitro fertilization and embryo transfer in a patient with endometrial cancer who was treated conservatively

Frontiers in Oncology, Journal Year: 2024, Volume and Issue: 14

Published: Dec. 11, 2024

To describe a patient conceiving with

Language: Английский

---